Cooper, O., Bonert, V., Rudnick, J., Pressman, B., & Melmed, S. (2019). SUN-442 EGFR/ErbB2 Targeted Therapy for Aggressive Prolactinomas. J Endocr Soc.
Chicago-stil citatCooper, Odelia, Vivien Bonert, Jeremy Rudnick, Barry Pressman, och Shlomo Melmed. "SUN-442 EGFR/ErbB2 Targeted Therapy for Aggressive Prolactinomas." J Endocr Soc 2019.
MLA-referensCooper, Odelia, et al. "SUN-442 EGFR/ErbB2 Targeted Therapy for Aggressive Prolactinomas." J Endocr Soc 2019.
Varning: dessa hänvisningar är inte alltid fullständigt riktiga.